Literature DB >> 9594936

Pharmacokinetics and pharmacology of terbinafine and itraconazole.

J Leyden1.   

Abstract

BACKGROUND: Two new systemic antifungal agents, terbinafine and itraconazole, have expanded the choices for treatment of onychomycosis. The pharmacokinetic and pharmacologic properties provide the basis of their activity and are related to their efficacy and safety in dermatophyte infections.
OBJECTIVE: We describe the pharmacodynamics, pharmacokinetics, and pharmacology of terbinafine and itraconazole and the features that form a framework for comparing their efficacy. PHARMACODYNAMICS: Both terbinafine and itraconazole ultimately block ergosterol synthesis; terbinafine disrupts fungal cell wall synthesis earlier (squalene to squalene epoxide) than does itraconazole (lanosterol to ergosterol). In vitro, terbinafine exposure results in a toxic accumulation of squalene and decreased production of ergosterol. Minimal inhibitory concentrations (MICs) of terbinafine for dermatophytes are essentially equal to minimal fungicidal concentrations (MFCs). However, the MFCs of itraconazole are much higher than the MICs. PHARMACOLOGIC PROFILE: Both itraconazole and terbinafine penetrate keratinizing tissue; levels reached in nail plate exceed those in plasma. Therapeutic levels of the itraconazole persist in nails for up to 6 months after discontinuation of 3 months of therapy (200 mg/day) and during various pulsed cycles. After discontinuation of 1 month of therapy, terbinafine persists at therapeutic levels in the nail. Itraconazole has an affinity for mammalian cytochrome P-450 enzymes as well as for fungal P-450-dependent enzyme, and thus has the potential for clinically important interactions (e.g., astemizole, terfenadine, rifampin, oral contraceptives, H2 receptor antagonists, warfarin, cyclosporine). Terbinafine is not metabolized through this system and has little potential for drug-drug interactions.
CONCLUSION: The low MFCs exhibited by terbinafine for dermatophytes may be important in its clinical efficacy and low relapse rates. The safety profile of terbinafine directly reflects its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9594936     DOI: 10.1016/s0190-9622(98)70483-9

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  16 in total

1.  Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine.

Authors:  Pranab K Mukherjee; Steven D Leidich; Nancy Isham; Ingrid Leitner; Neil S Ryder; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 2.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches.

Authors:  Mary A Davis; Dustyn A Barnette; Noah R Flynn; Anirudh S Pidugu; S Joshua Swamidass; Gunnar Boysen; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2019-04-10       Impact factor: 3.739

4.  Drug combinations against Mucor irregularis in vitro.

Authors:  Shuzhen Zhang; Ruoyu Li; Jin Yu
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

5.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Silicon phthalocyanine 4 phototoxicity in Trichophyton rubrum.

Authors:  Minh Lam; Matthew L Dimaano; Patricia Oyetakin-White; Mauricio A Retuerto; Jyotsna Chandra; Pranab K Mukherjee; Mahmoud A Ghannoum; Kevin D Cooper; Elma D Baron
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  Itraconazole attenuates hepatic gluconeogenesis and promotes glucose uptake by regulating AMPK pathway.

Authors:  Ri-Su Na; Cong Ma; Qiao-Rui Liu; Li-Ming Wu; Xu-Lei Zheng; Zhi-Wen Liu
Journal:  Exp Ther Med       Date:  2017-12-06       Impact factor: 2.447

8.  Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses.

Authors:  Whitney M Holden; Alexander R Ebert; Peter F Canning; Louise A Rollins-Smith
Journal:  Appl Environ Microbiol       Date:  2014-04-25       Impact factor: 4.792

9.  Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches.

Authors:  Dustyn A Barnette; Mary A Davis; Na L Dang; Anirudh S Pidugu; Tyler Hughes; S Joshua Swamidass; Gunnar Boysen; Grover P Miller
Journal:  Biochem Pharmacol       Date:  2018-08-02       Impact factor: 5.858

10.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.